Phase II Trial of RAD001 in Refractory Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT00337545
- Lead Sponsor
- Swedish Medical Center
- Brief Summary
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
- Detailed Description
Study is completed and closed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
- Measurable disease
- ECOG 0-2
Exclusion Criteria
- CNS disease
- Chemotherapy or radiotherapy < 4 weeks prior
- Active bleeding diathesis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of RAD001 (everolimus) target mTOR pathway dysregulation in refractory colorectal cancer?
How does RAD001 compare to standard-of-care therapies in metastatic colorectal cancer with prior resistance to chemotherapy and biologics?
Which biomarkers predict response to RAD001 in metastatic colorectal cancer patients with prior exposure to multiple chemotherapies?
What are the key adverse events associated with RAD001 in refractory colorectal cancer and how are they managed in clinical practice?
What combination therapies with mTOR inhibitors like RAD001 show promise in overcoming resistance in metastatic colorectal cancer?
Trial Locations
- Locations (1)
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
Swedish Cancer Institute🇺🇸Seattle, Washington, United States